摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[7-iodo-9-(4-methyl-piperazin-1-ylmethyl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]-methanol | 173419-31-3

中文名称
——
中文别名
——
英文名称
[7-iodo-9-(4-methyl-piperazin-1-ylmethyl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]-methanol
英文别名
[7-iodo-9-[(4-methyl-piperazinyl)methyl]-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]-methanol;[7-Iodo-9-(4-methylpiperazin-1-ylmethyl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]-methanol;[7-iodo-9-[(4-methylpiperazin-1-yl)methyl]-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]methanol
[7-iodo-9-(4-methyl-piperazin-1-ylmethyl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]-methanol化学式
CAS
173419-31-3
化学式
C18H22IN3O3
mdl
——
分子量
455.295
InChiKey
HWMROAICMNSQKR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    571.5±50.0 °C(Predicted)
  • 密度:
    1.631±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    58.1
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Convergent catalytic asymmetric synthesis of camptothecin analog GI147211C
    摘要:
    The topoisomerase I inhibitor G1147211C (4) was discovered at Glare Wellcome and shown to have promising anti-cancer properties. In order to fully assess the clinical potential of 3, an improved synthesis of the: drug substance was required. Herein is described a convergent catalytic asymmetric synthesis of 4 which utilizes as key steps, two Heck reactions, a Sharpless asymmetric dihydroxylation reaction, and a Mitsunobu reaction. A 2-chloroquinoline is shown to be a viable substrate for the final Heck reaction to generate the camptothecin nucleus. (C) 1997 Elsevier Science Ltd.
    DOI:
    10.1016/s0040-4020(97)00357-8
  • 作为产物:
    描述:
    7-iodo-9-(4-methyl-piperazin-1-ylmethyl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-carbaldehyde 在 sodium tetrahydroborate 作用下, 以 甲醇 为溶剂, 反应 2.0h, 以83%的产率得到[7-iodo-9-(4-methyl-piperazin-1-ylmethyl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]-methanol
    参考文献:
    名称:
    Convergent catalytic asymmetric synthesis of camptothecin analog GI147211C
    摘要:
    The topoisomerase I inhibitor G1147211C (4) was discovered at Glare Wellcome and shown to have promising anti-cancer properties. In order to fully assess the clinical potential of 3, an improved synthesis of the: drug substance was required. Herein is described a convergent catalytic asymmetric synthesis of 4 which utilizes as key steps, two Heck reactions, a Sharpless asymmetric dihydroxylation reaction, and a Mitsunobu reaction. A 2-chloroquinoline is shown to be a viable substrate for the final Heck reaction to generate the camptothecin nucleus. (C) 1997 Elsevier Science Ltd.
    DOI:
    10.1016/s0040-4020(97)00357-8
点击查看最新优质反应信息

文献信息

  • Preparation of a camptothecin derivative by intramolecular cyclisation
    申请人:Glaxo Wellcome Inc.
    公开号:US06063923A1
    公开(公告)日:2000-05-16
    The present invention relates to a method for the preparation of camptothecin and camptothecin-like compounds and to novel intermediates used in this preparation. In particular, the invention provides a process for the preparation of the camptothecin derivative of formula (I') known by the chemical name "7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20(R,S)-camptothecin ", which comprises cyclising the compound of formula (II'), wherein X is halogen, particularly chloro, bromo, or iodo; and when the compound of formula (I') is obtained as a mixture of enantiomers optionally resolving the mixture to obtain the desired enantiomer, and/or if desired, converting the resulting compound of formula (I') or a salt thereof into a physiologically acceptable salt or solvate thereof.
    本发明涉及一种制备喜树碱和类喜树碱化合物的方法,以及在该制备过程中使用的新型中间体。具体而言,该发明提供了一种制备化学名称为“7-(4-甲基哌嗪甲烯)-10,11-乙二氧基-20(R,S)-喜树碱”(分子式为(I')的喜树碱生物的方法,其中包括将分子式为(II')的化合物环化,其中X为卤素,特别是;当以对映体混合物形式获得分子式为(I')的化合物时,可选择性地分离混合物以获得所需对映体,或者如有需要,将得到的分子式为(I')的化合物或其盐转化为其生理上可接受的盐或溶剂化合物。
  • [EN] PREPARATION OF A CAMPTOTHECIN DERIVATIVE BY INTRAMOLECULAR CYCLISATION<br/>[FR] PREPARATION DE DERIVES DE LA CAMPTOTHECINE PAR CYCLISATION INTRAMOLECULAIRE
    申请人:GLAXO WELLCOME INC.
    公开号:WO1995029919A1
    公开(公告)日:1995-11-09
    (EN) The present invention relates to a method for the preparation of camptothecin and camptothecin-like compounds and to novel intermediates used in this preparation. In particular, the invention provides a process for the preparation of the camptothecin derivative of formula (I') known by the chemical name '7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20(R,S)-camptothecin', which comprises cyclising the compound of formula (II'), wherein X is halogen, particularly chloro, bromo, or iodo; and when the compound of formula (I') is obtained as a mixture of enantiomers optionally resolving the mixture to obtain the desired enantiomer; and/or if desired, converting the resulting compound of formula (I') or a salt thereof into a physiologically acceptable salt or solvate thereof.(FR) L'invention porte sur une méthode de préparation de la camptothécine et de ses analogues, et sur de nouveaux intermédiaires servant à cette préparation; elle porte en particulier sur une méthode de préparation d'un dérivé de la camptothécine de formule (I') dit '7-(4-méthylpipérazinométhylène)-10,11-éthylénodioxy-20(R, S)-campothécine', obtenu par cyclisisation du composé de formule (II'), où X est halogène (en particulier chloro, bromo ou iodo), et dans lequel le composé de formule (I') est obtenu à partir d'un mélange d'énantiomères en résolvant éventuellement le mélange pour obtenir l'énantiomère désiré, et/ou en convertissant facultativement le composé résultant de formule (I') ou l'un de ses sels, en un sel physiologiquement acceptable ou en l'un de ses solvates.
    本发明涉及一种制备喜树碱和类喜树碱化合物的方法以及在该制备中使用的新型中间体。具体而言,本发明提供了一种制备喜树碱生物的方法,该衍生物化学名称为“7-(4-甲基哌嗪亚甲基)-10,11-乙二氧基-20(R,S)-喜树碱”,其中包括将式(I')的化合物环化,其中X为卤素,特别是;如果式(I')的化合物以对映体混合物的形式获得,则可以选择性地分离混合物以获得所需的对映体;如果需要,则将所得的式(I')化合物或其盐转化为其生理上可接受的盐或溶剂化物。
  • [EN] METHOD FOR PREPARING CAMPTOTHECIN DERIVATIVES<br/>[FR] PROCEDE POUR PREPARER DES DERIVES DE CAMPTOTHECINE
    申请人:GLAXO WELLCOME INC.
    公开号:WO1997016454A1
    公开(公告)日:1997-05-09
    (EN) The present invention relates to a process for preparing camptothecin and camptothecin analogs of Formula (I) from compounds of Formula (II) and to novel intermediates useful in their preparation, wherein R1 to R6 represent various substituents.(FR) Cette invention se rapporte à un procédé pour préparer de la camptothécine et des analogues de camptothécine de formule (I) à partir de composés de formule (II), ainsi qu'à de nouveaux intermédiaires servant à leur préparation, formules dans lesquelles R1 à R6 représentent divers substituants.
    该发明涉及一种从公式(II)化合物制备公式(I)的喜树碱喜树碱类似物的过程,以及其制备中有用的新型中间体,其中R1至R6代表不同的取代基。
  • Method of removing heavy metal contaminants from organic compounds
    申请人:Glaxo Wellcome, Inc.
    公开号:US05840898A1
    公开(公告)日:1998-11-24
    A process for removal of heavy metal contaminants from organic compounds, especially campthothecin analogs.
    一种用于从有机化合物中去除重属污染物的过程,特别是用于去除喜树碱类似物中的重属。
  • Preparation of a camptothecin derivative by intramolecular cyclization
    申请人:OSI Pharmaceuticals, Inc.
    公开号:US06462196B1
    公开(公告)日:2002-10-08
    The present invention relates to a method for the preparation for camptothecin and camptothecin-like compounds and to novel intermediates used in this preparation. In particular, the invention provides a process for the preparation of the camptothecin derivative of formula (I′) known by the chemical name “7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20(R,S)-camptothecin”, which comprises cyclising the compound of formula (II′), wherein X is halogen, particularly chloro, bromo, or iodo; and when the compound of formula (I′) is obtained as a mixture of enantiomers optionally resolving the mixture to obtain the desired enantiomer; and/or if desired, converting the resulting compound of formula (I′) or a salt thereof into a physiologically acceptable salt or solvate thereof.
    本发明涉及一种制备喜树碱和类喜树碱的方法,以及在该制备过程中使用的新型中间体。具体而言,本发明提供了一种制备喜树碱生物的方法,该衍生物化学名称为“7-(4-甲基哌嗪亚甲基)-10,11-环氧-20(R,S)-喜树碱”,包括环化式(II')的化合物,其中X是卤素,特别是;当式(I')化合物以对映体的混合物形式获得时,可以选择分离混合物以获得所需的对映体;如果需要,可以将所得的式(I')化合物或其盐转化为其生理上可接受的盐或溶剂。
查看更多